Xsolla Expands Mobile and Digital Distribution Solution Offerings and Adds an NFT Checkout to the Growing Set of Tools and Services for Developers
Xsolla, a global video game commerce company, announced today that it has expanded their mobile and digital distribution solutions to provide more opportunities for developers to launch and grow their games around the world. In addition, Xsolla has added a new checkout feature to help developers scale their brands by selling and distributing NFTs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220428005554/en/
XSOLLA EXPANDS MOBILE AND DIGITAL DISTRIBUTION SOLUTION OFFERINGS AND ADDS AN NFT CHECKOUT TO THE GROWING SET OF TOOLS AND SERVICES FOR DEVELOPERS (Graphic: Business Wire)
“Xsolla is committed to providing best-in-class services and support for developers worldwide to help them reach more players in more geographies,” stated Chris Hewish, President of Xsolla. “We continue to develop new features that target the key challenges of marketing, launching, and monetizing video games. We have more to come in 2022 that will keep our partners ahead of the constantly evolving game climate.”
Mobile Web Shop - New Features
As the expanding mobile landscape continues to lead global gaming revenue, Xsolla’s Web Shop for Mobile Games has added new features to help mobile developers to reach more players and to remain at the forefront of the mobile gaming revolution.
● Expanded Analytics
Developers can create a transparent funnel that will increase efficiency in bringing new players to their Web Shop. This will help developers understand the player experience online and determine where and how users engage with their game.
● Unique Promotions
This built-in component helps developers benefit from in-app purchases through their Web Shop. Within the online experience, developers can provide promotional offers and launch discount campaigns, promo code offers, and bonuses to boost sales and bring new players online.
● Subscriptions Management
To help developers sell a complete catalog of digital goods in their Web Shop, Xsolla added robust subscription features. This allows developers to gain and retain new customers, create loyalty, generate reliable revenue streams, and manage subscriptions with confidence.
For more information about the Xsolla Web Shop, visit: https://xsolla.com/solution/web-shop-for-mobile-games
NFT Checkout
Xsolla has created an NFT Checkout process to allow developers to quickly and securely add NFTs to their game economy. This feature enables players to make purchases using their preferred payment method. The developer handles the minting and the delivery of the NFTs, while Xsolla handles the checkout and in-game items distribution process.
For more details about NFT Checkout, visit: https://xsolla.com/solution/payments/nft-checkout
Digital Distribution Hub
Xsolla Digital Distribution Hub connects games to a global network of apps, internet service providers (ISPs), banks, and other channels to help developers reach players and gain revenue from every transaction. This new solution empowers gamers to discover and support their favorite games through an optimized multi-platform experience and allows them to pay how and when they want.
Developers can now benefit from increased market penetration and brand awareness through distribution channels, such as super apps, online banking apps and mobile carrier marketplaces. With the Digital Distribution Hub your game can reach a vast audience of new users, save on distribution costs, and boost overall revenue and engagement.
To learn more about Digital Distribution Hub, visit: https://xsolla.com/products/digital-distribution-hub
Xsolla will present these solutions and more at several upcoming events, including GamesBeat Summit 2022, Pocket Gamer Connects Seattle, Nordic Game Show, Pocket Gamer Toronto, China Joy, and gamescom, in the next six months. Register to meet up with the experts at Xsolla by visiting: https://xsolla.com/events.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Berlin, Seoul, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Ubisoft, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005554/en/
Contact information
Derrick Stembridge
Director of Public Relations, Xsolla
d.stembridge@xsolla.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom